Xcout Intel
Azalea Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Azalea Therapeutics among biotech companies — ranked by similarity to what Azalea Therapeutics actually does, not by market-cap band.
Subscribe to see Azalea Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Azalea Therapeutics
Azalea Therapeutics is a biotechnology company headquartered in Berkeley, California. The company focuses on precision genome engineering directly inside the body with an initial emphasis on developing in vivo cancer immunotherapies.
Azalea Therapeutics at a glance
Azalea Therapeutics is a biotech company headquartered in United States. It has raised at least $82M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $65M in November 2025. Xcout tracks 15 named people at Azalea Therapeutics, including Jenny Hamilton (Co-founder, President and Chief Executive Officer).
Azalea Therapeutics leadership
- Jenny HamiltonCo-founder, President and Chief Executive Officer
- Paul WestbergChief Business Officer
- Jenny Hamiltonco-founder, president and chief executive officer
- Abdullah Syedscientific co-founder
- Connor Tsuchidascientific co-founder
- Jennifer Doudnaco-founder
9 more named people on record for Azalea Therapeutics, with roles, board committees and tenure — see the full roster →
Azalea Therapeutics funding rounds
At least $82M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $65M | 4 named | |
| — | $17M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Azalea Therapeutics competitors
Ranked by semantic similarity — how close each company is to Azalea Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Biotechnology
Ray Therapeutics, Inc. is a privately held optogenetic gene therapy company headquartered in Berkeley, California. The company focuses on reimagining vision through innovative genetic treatments and novel therapeutic solutions.
Biotechnology
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Similar biotech company
Tessera Therapeutics is a biotechnology company developing programmable genetic medicines using its Gene Writing technology, which is based on mobile genetic elements to insert, replace, or modify DNA in cells. It aims to develop treatments for genetic diseases and other serious conditions, serving patients who need durable genetic therapies.
Biotechnology
GeneTether, Inc., also known as Rize Oncology, is a biotechnology company headquartered in San Lorenzo, California, focused on developing proprietary gene-editing technologies and targeted oncology therapeutics.
Life Sciences
Acrigen Biosciences, Inc. is a biotechnology company headquartered in California, United States. The firm is developing precision gene editing systems and delivery technologies to control CRISPR applications and provide advanced genetic medicines. Its research is conducted in collaboration with academic groups such as UCSF.
Biotechnology
Tune Therapeutics, Inc. is a biotechnology company founded in 2020 that develops advanced genomic and epigenetic therapies, including epigenetic silencers.
Biotechnology
Fauna Bio is a biotechnology company headquartered in Berkeley, California. The company combines animal genomics and advanced data approaches to drive drug discovery and improve human health.
Similar biotech company
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Similar biotech company
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Biotechnology
BreezeBio is a biotechnology company headquartered in the South San Francisco area of California that develops precision genetic medicines.
Similar biotech company
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Azalea Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Azalea Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →